Clario vs ICON plc

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/clario/iconplc

Category	Clario	ICON plc
Listed site	cro	cro
Summary	Clario provides comprehensive clinical trial endpoint solutions spanning cardiac safety, eCOA, medical imaging, respiratory, and precision motion analysis, supporting approximately 70% of FDA and EMA novel drug approvals over the past decade.	ICON is a world-leading clinical research organization providing outsourced services across the full clinical trial lifecycle, from early phase through commercialization, to pharmaceutical, biotechnology, and medical device companies.
Services	Clinical Imaging Core Lab Data Management & eClinical Clinical Operations Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Biostatistics & Statistical Programming Regulatory Affairs Cardiovascular & Metabolic Specialty Services Central Laboratory Services Clinical Trial Services US FDA Regulatory Strategy EU EMA Regulatory Strategy Medical Writing CNS Specialty Services	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Flow Cytometry Services Bioanalysis Translational Research Biomarker Assays Immunogenicity Assays (ADA / NAb) Ligand-Binding Bioanalysis (Large Molecule) LC-MS Bioanalysis (Small Molecule) Cardiovascular & Metabolic Specialty Services CNS Specialty Services Oncology Specialty Services Immunology & Inflammation Services Companion Diagnostics Development Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Vaccine	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Vaccine
Indications	Cardiovascular Metabolic Dermatology Infectious Disease Gastroenterology Neurology Oncology Ophthalmology Respiratory Women's Health Rare Disease Immunology	Cardiovascular Neurology Immunology Oncology Infectious Disease Metabolic Rare Disease Women's Health Ophthalmology
Locations	Global Operations, Multiple (100+ countries)	Headquarters, Dublin, Ireland Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico United States, United States, United States
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.